David Lebowitz
Stock Analyst at Citigroup
(0.81)
# 1994
Out of 5,319 analysts
112
Total ratings
45.71%
Success rate
-7.89%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
PLRX Pliant Therapeutics | Maintains: Neutral | 4 2 | 1.46 | 2.74% | 6 | Mar 4, 2025 | |
NTLA Intellia Therapeutic... | Maintains: Neutral | 12 14 | 7.23 | 93.64% | 7 | Feb 28, 2025 | |
BBIO BridgeBio Pharma | Maintains: Strong Buy | 45 49 | 33.87 | 44.67% | 3 | Feb 21, 2025 | |
IONS Ionis Pharmaceutical... | Maintains: Buy | 67 64 | 28.4 | 125.35% | 12 | Feb 20, 2025 | |
EXEL Exelixis | Maintains: Strong Buy | 38 45 | 36.19 | 24.34% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 47.39 | -5.04% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 97 88 | 58.21 | 51.18% | 5 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 38 | 23.94 | 58.73% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 86 | 39.48 | 117.83% | 1 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 39.1 | 73.91% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 18.3 | 282.51% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 13 15 | 4.37 | 243.25% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 178 207 | 165.05 | 25.42% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 65 76 | 84.69 | -10.26% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 39 37 | 25.75 | 43.69% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 301.66 | 26.63% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 59.17 | 62.24% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 1.27 | 844.88% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 234.56 | -30.08% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 13.01 | 199.77% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 11.54 | 81.98% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 4.95 | 8081.82% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 0.73 | 1817.81% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | 1.4 | 21328.57% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | n/a | n/a | 2 | Aug 10, 2021 |